论文部分内容阅读
目的探讨头孢哌酮舒巴坦联合依替米星治疗铜绿假单胞菌感染患者支气管扩张症的临床疗效。方法选取2014年6月至2015年6月医院收治的100例铜绿假单胞菌感染的支气管扩张症患者作为研究对象,将其采用随机数字表法分为对照组与试验组,各50例。对照组患者采取头孢哌酮舒巴坦治疗,试验组采取头孢哌酮舒巴坦联合依替米星治疗,治疗10 d后进行比较观察。结果经治疗后,对照组患者总有效率明显低于试验组,细菌清除率明显高于对照组,差异均有统计学意义(均P<0.05);试验组和对照组患者白细胞计数均明显高于治疗前,且试验组患者的白细胞计数明显高于对照组,差异均有统计学意义(均P<0.05)。讨论对于由铜绿假单胞菌感染引起的支气管扩张患者,采用头孢哌酮舒巴坦联合依替米星治疗,临床效果显著,细菌清除率高。
Objective To investigate the clinical efficacy of cefoperazone-sulbactam combined with etimicin in the treatment of bronchiectasis in patients with Pseudomonas aeruginosa infection. Methods 100 cases of Pseudomonas aeruginosa-infected patients with bronchiectasis admitted from June 2014 to June 2015 in our hospital were selected as study subjects and divided into control group and trial group with 50 cases in each group. The patients in the control group were treated with cefoperazone sulbactam. The patients in the test group were treated with cefoperazone-sulbactam combined with etimicin. After 10 days of treatment, the patients were compared. Results After treatment, the total effective rate in the control group was significantly lower than that in the experimental group, and the bacterial clearance rate was significantly higher than that in the control group (all P <0.05). The white blood cell count of the experimental group and the control group were significantly higher Before treatment, and the test group of patients with leukocyte count was significantly higher than the control group, the difference was statistically significant (P <0.05). Discussion In patients with bronchiectasis caused by Pseudomonas aeruginosa infection, cefoperazone / sulbactam combined with etimicin has significant clinical benefit and high bacterial clearance.